Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?
Authors:
- Ahmed AlnughmushAAAhmed Alnughmush
- Ayman SayyedASAyman Sayyed
- Mats RembergerMRMats Remberger
- Eshrak Al-ShaibaniEAEshrak Al-Shaibani
- Carol Bsc ChenCCCarol Bsc Chen
- Ivan PasicIPIvan Pasic
- Igor Novitzky-BassoINIgor Novitzky-Basso
- Arjun Datt LawALArjun Datt Law
- Wilson LamWLWilson Lam
- Dennis (Dong Hwan) KimDKDennis (Dong Hwan) Kim
- Armin GerbitzAGArmin Gerbitz
Open Access
- 9 January 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (2) , e1753
Abstract
Background.: Despite decades of post–allogeneic hematopoietic cell transplantation (HCT) growth factor utilization, its role remains undefined, leading to ongoing debates and research. The theoretical impacts of growth factors have been challenged in numerous studies. Methods.: In this retrospective cohort study conducted at the Princess Margaret Cancer Centre, we analyzed the clinical outcomes of 509 patients who underwent allogeneic HCT between May 1, 2019, and May 31, 2022. This study aimed to assess the impact of granulocyte colony-stimulating factor (G-CSF) administration posttransplantation on neutrophil and platelet engraftment, incidence of bloodstream infections (BSIs), graft-versus-host disease, engraftment syndrome (ES), and survival metrics including overall survival, nonrelapse mortality, and graft-versus-host disease–free/relapse-free survival. Results.: Our findings indicate that G-CSF administration expedited neutrophil engraftment (16 versus 18 d, P = 0.009) and was associated with a decreased incidence of BSI (9.4% versus 31.3%, P = 0.014). However, this benefit was counterbalanced by a significant delay in platelet engraftment (21 versus 17 d, P < 0.001). Multivariate logistic regression analysis identified mismatched donors (odds ratio, 1.72; 95% confidence interval, 1.03-2.88; P = 0.038) and the duration of G-CSF therapy (odds ratio, 1.04; 95% confidence interval, 1.00-1.09; P = 0.038) as independent predictors for the development of ES. Despite these hematological impacts, there was no observed advantage in overall survival, nonrelapse mortality, or graft-versus-host disease–free/relapse-free survival among patients who received G-CSF compared with those who did not. Conclusions.: Although G-CSF post-HCT expedited neutrophil engraftment and reduced BSI risk, it did not result in a survival advantage. The association with ES necessitates careful consideration.Keywords
This publication has 34 references indexed in Scilit:
- Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: Uses, misuses, misconceptions, and future applicationsExperimental Hematology, 2005
- Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2004
- The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysisBone Marrow Transplantation, 2003
- G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IVBone Marrow Transplantation, 2003
- Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteriaBone Marrow Transplantation, 2003
- Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen–matched related donorsBlood, 2001
- Engraftment syndrome following hematopoietic stem cell transplantationBone Marrow Transplantation, 2001
- Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantationBone Marrow Transplantation, 2000
- A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.2000
- Filgrastim as an Alternative to Donor Leukocyte Infusion for Relapse After Allogeneic Stem-Cell TransplantationJournal of Clinical Oncology, 2000